Barclays Maintains an 'Overweight' on Teva Pharma (TEVA); Detailed Laquinimod Results Support Our Positive View
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $39.34 -0.38%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade TEVA Now!
Barclays maintains an 'Overweight' on Teva Pharma (NASDAQ: TEVA), PT $70.
Barclays analyst says, "First-time detailed laquinimod Phase 3 results support previously-disclosed top line data with solid safety & efficacy profile: Last night, Teva announced eagerly awaited details of the ALLEGRO study and hosted a conference call - the timing of the event having come earlier than the previously expected April 14 date, and ahead of the presentation at AAN on April 15. Encouragingly, the two key efficacy endp oints were within our expectations -- relative to placebo, laquinimod demonstrated a statistically significant 23% reduction in annualized relapse rate (p=0.0024) - the primary endpoint - and a 36% reduction in risk of confirmed disability progression as measured by EDSS (p=0.0122). More importantly, safety data confirmed positive Phase 2 results, particularly critical given that this is a key differentiator relative to the only marketed oral MS drug, Novartis's Gilenya, and orals in development."
"Yesterday's stock weakness provides attractive opportunity: With the stock trading at under 10x our FY11 EPS estimate, we reiterate our 1-OW rating, and view of Teva as the most attractive stock in our coverage universe."
For more ratings news on Teva Pharma click here and for the rating history of Teva Pharma click here.
Shares of Teva Pharma closed at $48.98 yesterday, with a 52 week range of $46.99-$63.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays analyst says, "First-time detailed laquinimod Phase 3 results support previously-disclosed top line data with solid safety & efficacy profile: Last night, Teva announced eagerly awaited details of the ALLEGRO study and hosted a conference call - the timing of the event having come earlier than the previously expected April 14 date, and ahead of the presentation at AAN on April 15. Encouragingly, the two key efficacy endp oints were within our expectations -- relative to placebo, laquinimod demonstrated a statistically significant 23% reduction in annualized relapse rate (p=0.0024) - the primary endpoint - and a 36% reduction in risk of confirmed disability progression as measured by EDSS (p=0.0122). More importantly, safety data confirmed positive Phase 2 results, particularly critical given that this is a key differentiator relative to the only marketed oral MS drug, Novartis's Gilenya, and orals in development."
"Yesterday's stock weakness provides attractive opportunity: With the stock trading at under 10x our FY11 EPS estimate, we reiterate our 1-OW rating, and view of Teva as the most attractive stock in our coverage universe."
For more ratings news on Teva Pharma click here and for the rating history of Teva Pharma click here.
Shares of Teva Pharma closed at $48.98 yesterday, with a 52 week range of $46.99-$63.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
